European LVAD registry
This article was originally published in The Gray Sheet
Executive Summary
Two-to-three year left-ventricular assist device registry will track patients in an effort to convince European governments of the quality of life benefits and spur reimbursement. Sparked by collaboration between Eucomed and LVAD manufacturers, the registry will focus both on bridge-to-transplant and destination therapy patients. In the U.S., a Medicare coverage decision for LVADs currently is slated for September, following several delays by CMS (1"The Gray Sheet" Aug. 18, 2003, p. 11)...